HR and breast cancer: The BC patients in our cohort were mainly grouped into the HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2− subtypes in accordance with the results of immunohistochemical staining, which accounted for 61.46%, 15.62%, 12.62%, and 10.30%, respectively.